Specify a stock or a cryptocurrency in the search bar to get a summary
Opthea Ltd
OPTOpthea Limited, a clinical-stage biopharmaceutical company, develops and commercializes drugs for eye diseases in Australia and the United States. Its development activities are based on the intellectual property portfolio covering vascular endothelial growth factors (VEGF) VEGF-C, VEGF-D, and VEGF Receptor-3 for the treatment of diseases associated with blood and lymphatic vessel growth, as well as vascular leakage. The company's lead product candidate is sozinibercept (OPT-302), a biologic drug in Phase 3 clinical trials designed to inhibit VEGF-C and VEGF-D and complement VEGF-A inhibitors for the treatment of wet age-related macular degeneration and diabetic macular edema. It serves the biotechnology and healthcare industries. The company was formerly known as Circadian Technologies Limited and changed its name to Opthea Limited in December 2015. Opthea Limited was incorporated in 1984 and is headquartered in South Yarra, Australia. Address: 650 Chapel Street, South Yarra, VIC, Australia, 3141
Analytics
WallStreet Target Price
7.18 AUDP/E ratio
–Dividend Yield
–Current Year
Last Year
Current Quarter
Last Quarter
Current Year
Last Year
Current Quarter
Last Quarter
Key Figures OPT
Dividend Analytics OPT
Dividend growth over 5 years
–Continuous growth
–Payout Ratio 5 years average
–Dividend History OPT
Stock Valuation OPT
Financials OPT
Results | 2019 | Dynamics |